Digumarthy Subba R, Mendoza Dexter P, Lin Jessica J, Rooney Marguerite, Do Andrew, Chin Emily, Yeap Beow Y, Shaw Alice T, Gainor Justin F
Department of Radiology, Massachusetts General Hospital, Boston, MA 02114, USA.
Massachusetts General Hospital Cancer Center and Department of Medicine, Massachusetts General Hospital, Boston, MA 02114, USA.
Cancers (Basel). 2020 Mar 15;12(3):693. doi: 10.3390/cancers12030693.
Rearranged during transfection proto-oncogene () fusions represent a potentially targetable oncogenic driver in non-small cell lung cancer (NSCLC). Imaging features and metastatic patterns of advanced fusion-positive (+) NSCLC are not well established. Our goal was to compare the imaging features and patterns of metastases in +, + and + NSCLC. Patients with +, +, or + NSCLC seen at our institution between January 2014 and December 2018 with available pre-treatment imaging were identified. The clinicopathologic features, imaging characteristics, and the distribution of metastases were reviewed and compared. We identified 215 patients with NSCLC harboring , , or gene fusion ( = 32; = 116; = 67). Patients with + NSCLC were older at presentation compared to + and + patients (median age: = 64 years; = 51 years, < 0.001; ROS = 54 years, = 0.042) and had a higher frequency of neuroendocrine histology ( = 12%; = 2%, = 0.025; = 0%, = 0.010). Primary tumors in + patients were more likely to be peripheral ( = 69%; = 47%, = 0.029; = 36%, = 0.003), whereas lobar location, size, and density were comparable across the three groups. + NSCLC was associated with a higher frequency of brain metastases at diagnosis compared to + NSCLC ( = 32%, = 10%; = 0.039. Metastatic patterns were otherwise similar across the three molecular subgroups, with high incidences of lymphangitic carcinomatosis, pleural metastases, and sclerotic bone metastases. + NSCLC shares several distinct radiologic features and metastatic spread with + and NSCLC. These features may suggest the presence of fusions and help identify patients who may benefit from further molecular genotyping.
转染期间重排的原癌基因()融合在非小细胞肺癌(NSCLC)中代表一种潜在可靶向的致癌驱动因素。晚期融合阳性(+)NSCLC的影像学特征和转移模式尚未完全明确。我们的目标是比较+、+和+ NSCLC的影像学特征和转移模式。确定了2014年1月至2018年12月在我们机构就诊且有可用治疗前影像学资料的+、+或+ NSCLC患者。回顾并比较了临床病理特征、影像学特征和转移分布情况。我们确定了215例患有、或基因融合的NSCLC患者(= 32;= 116;= 67)。与+和+患者相比,+ NSCLC患者就诊时年龄更大(中位年龄:= 64岁;= 51岁,< 0.001;ROS = 54岁,= 0.042),神经内分泌组织学频率更高(= 12%;= 2%,= 0.025;= 0%,= 0.010)。+患者的原发性肿瘤更可能位于外周(= 69%;= 47%,= 0.029;= 36%,= 0.003),而叶的位置、大小和密度在三组中具有可比性。与+ NSCLC相比,+ NSCLC在诊断时脑转移频率更高(= 32%,= 10%;= 0.039)。在其他方面,三种分子亚组的转移模式相似,淋巴管癌病、胸膜转移和硬化性骨转移发生率较高。+ NSCLC与+和 NSCLC具有一些不同的放射学特征和转移扩散情况。这些特征可能提示融合基因的存在,并有助于识别可能从进一步分子基因分型中获益的患者。